Immune checkpoint expression as prognostic biomarker candidates in non-small cell lung carcinoma patients
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Soluble Glucocorticoid-induced tumor necrosis factor receptor family-related receptor (sGITR), its ligand (sGITRL), and soluble OX40L are promising prognostic biomarkers for non-small cell lung cancer (NSCLC). These biomarkers may also serve as novel immunotherapy targets in NSCLC patients.
Area Of Science
- Oncology
- Immunology
- Biomarker Discovery
Background
- Cancer immunotherapy, particularly checkpoint inhibitors, is vital for non-small cell lung cancer (NSCLC) treatment.
- Exploring novel prognostic biomarkers in peripheral blood is crucial for NSCLC management.
- Investigated biomarkers include soluble OX40 (sOX40), OX40L (sOX40L), Glucocorticoid-induced tumor necrosis factor receptor family-related receptor (GITR), GITR ligand (GITRL), 4-1BB (TNFRS9), and ICOS.
Purpose Of The Study
- To evaluate the potential of specific soluble immune checkpoint-related proteins as prognostic biomarkers in NSCLC patients.
- To identify associations between these biomarkers and clinical factors like smoking status, sex, and disease stage.
Main Methods
- Analyzed peripheral blood samples from 58 advanced NSCLC patients diagnosed between January 2019 and March 2020.
- Measured levels of sOX40, sOX40L, sGITR, sGITRL, 4-1BB, and ICOS.
Main Results
- Smokers with NSCLC showed higher sOX40 and lower s4-1BB levels compared to non-smokers.
- Lower sOX40L levels were observed in males versus females (p < 0.05).
- Stage III NSCLC patients had higher sOX40 and sGITRL levels than Stage IV patients (p < 0.05).
- High sGITR, sGITRL, and sOX40L levels correlated with significantly different survival rates (p < 0.05).
Conclusions
- sGITR, sGITRL, and sOX40L are identified as potential prognostic biomarkers for NSCLC.
- These biomarkers may represent novel therapeutic targets for immunotherapy in NSCLC.
- Biomarker levels are associated with clinical characteristics including smoking, sex, disease stage, and age.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
